Close Menu

Sophia Genetics

The deal will allow users of MGI's DNBSEQ sequencers to convert previously validated assays to the platform and access Sophia's analytics technology. 

With the partnership, the companies aim to help researchers streamline their workflows from sample collection to enrichment to interpretation. 

Users can apply both companies' tools to view genomic evidence linked to disease mutations, reducing the time needed to examine a variant's pathogenicity.

In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.

Sophia's STS molecular diagnostic application runs on top of the Sophia AI platform to detect and characterize genomic alterations in solid tumors.

The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.

At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.